Gain Therapeutics stockholders approve doubling authorized common stock to 100M shares

Gain Therapeutics, Inc.

Stockholders approved amendment to increase authorized common shares from 50M to 100M.
All eight director nominees elected; Ernst & Young AG ratified as auditor for FY2025.
Vote results: 16.3M for share increase, 2.2M against, 12k abstain; 18.0M ratified auditor.
Adjournment proposal also approved to allow further proxy solicitation if needed.

item 5.03item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.